Insights about U.S. Stocks that landed in the Red-Zone during Wednesday’s trade, are depicted underneath:
Synergy Pharmaceuticals Inc (NASDAQ:SGYP)’s shares dwindled -4.55%, and closed at $3.15. With recent incline, the year-to-date (YTD) performance reflected a +3.28% gain above last year. During the past month the stocks gain 10.14%, bringing three-month performance to 8.25% and six-month performance to -17.97%. The mean recommendation of analysts for this stock is 1.80. (where 1=Buy, 5=Sale).
Synergy Pharmaceuticals Inc., a biopharmaceutical corporation, focuses on the development of drugs to treat gastrointestinal (GI) disorders and diseases.
Quiksilver, Inc (NYSE:ZQK), declined -4.52%, and closed at $1.90.
Quiksilver Inc. (ZQK), declared that it has postponed the distribution of its 2015 first quarter earnings release, in addition to the related conference call and webcast formerly planned to take place on March 5th, as a result of a proceed cut-off issue identified by administration and brought to the attention of the Audit Committee.
The Audit Committee promptly commenced an investigation last week and has not yet reached any conclusions. Based on presently accessible information, the Corporation believes that the completion of the Audit Committee’s investigation will have no material influence on its formerly issued financial statements, its 2015 first quarter financial results, or its current guidance.
The Audit Committee plans to review progress regarding its investigation at a formerly planned regular meeting of the Board of Directors on March 16th, after which the Corporation anticipates announcing a date for distribution of its first quarter 2015 financial results during March.
Quiksilver, Inc. designs, develops, and distributes branded apparel, footwear, accessories, and related products primarily for men, women, and children. The corporation provides its products for various activities, counting casual and outdoor lifestyle associated with surfing, skateboarding, snowboarding, BMX and motocross, rally car, and other activities.
Chesapeake Energy Corporation (NYSE:CHK), dipped -4.38%, and closed at $15.49, hitting new 52-week low of $15.32.
Formerly on February 25, Chesapeake Energy Corporation (CHK), stated financial and operational results for the 2014 full year and fourth quarter and declared details of its 2015 Outlook and capital expenditure program.
2015 Capital Program and Production Outlook:
Chesapeake is budgeting total capital expenditures (counting capitalized interest) of $4.0 $4.5 billion for 2015. Using the midpoint of the range, this represents a 26% reduction from the corporation’s 2014 capital expenditures before attainments of $5.8 billion, and a 37% reduction from the corporation’s 2014 total capital expenditures of about $6.7 billion. The corporation is targeting 2015 production of 235 240 million barrels of oil equivalent (mmboe), or average daily production of 645 655 thousand barrels of oil equivalent (mboe), which represents 3 5% production growth after adjusting for 2014 asset sales. Of the 2015 projected production, about 39 40 mmboe is estimated to be crude oil, 1,035 1,055 billion cubic feet (bcf) natural gas and 23 24 mmboe natural gas liquids (NGL).
Chesapeake plans to operate 35 45 rigs in 2015, which represents the corporation’s lowest operated rig activity level since 2004 and a decrease of about 38% (using the midpoint of the range) from an average of 64 rigs in 2014. The corporation intends to spud about 790 gross operated wells and connect to sales about 800 gross operated wells in 2015, a decrease from about 1,175 and 1,150 wells, respectively, in 2014.
Chesapeake Energy Corporation engages in the attainment, exploration, and development of properties for the production of oil, natural gas and natural gas liquids (NGL) from underground reservoirs in the United States.
Achillion Pharmaceuticals, Inc (NASDAQ:ACHN), dropped -4.20%, and closed at $11.63.
Formerly on February 18, Achillion Pharmaceuticals, Inc. (ACHN), declared the closing of its formerly declared public offering of ordinary stock. Achillion sold 13,800,000 shares of its ordinary stock in the offering at a price to the public of $10.25 per share, counting the exercise in full by the underwriters of their option to purchase an additional 1,800,000 shares of ordinary stock at the public offering price. Achillion received net proceeds of about $132.7 million, after deducting underwriting discounts and commissions and estimated offering expenses.
Leerink Partners LLC and Deutsche Bank Securities Inc. acted as joint book-running managers, Wells Fargo Securities, LLC acted as lead manager, and JMP Securities LLC acted as co-manager for the offering.
The offering was made by Achillion following a shelf registration statement formerly filed with and declared effective by the Securities and Exchange Commission (“SEC”).
Achillion is an innovative pharmaceutical corporation dedicated to bringing important new treatments to patients with infectious disease. Achillion’s pipeline is presently focused on small molecule therapeutics for infectious disease and complement-related diseases.
